Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

The Europe Alzheimer’s disease therapeutics and diagnostics market is expected to grow at 7.51% of CAGR over the forecast period of 2019-2027.

The economies studied in the Europe Alzheimer’s disease therapeutics and diagnostics market are:

•       The United Kingdom

•       France

•       Germany

•       Spain

•       Italy

•       Russia

•       Rest of Europe

Alzheimer’s is a neurodegenerative disorder that causes side-effects like memory loss and behavioral & thinking challenges. In the early stages of this disease, memory loss is comparatively mild, but with progression, the individuals lose their ability to carry a conversation and respond to the environment. In addition, very few therapeutic alternatives are available in the market, which do not provide a complete cure to the disease. These factors indicate the need to provide advanced treatment, which are key opportunities for the market and the companies actively operating in it. 

Witnessing a sudden rise in the registered cases of Alzheimer’s in European countries, the demand for Alzheimer’s diagnostic tests and new drug development is expected to surge over the forecasted years. Geographically, in terms of the neurological drug market, Germany holds a significant share compared to other countries. However, complex and restricted rules for claiming medical reimbursement and expensive treatment of Alzheimer’s is majorly affecting the growth of the Alzheimer’s disease therapeutics and diagnostics market in these regions. In recent times, awareness initiatives regarding Alzheimer’s have increased considerably. As a result, European governments have started investing heavily in the R&D department.

Roche Ltd. provides products in almost every medical and pharmaceutical segment. It has developed ‘Gantenerumab,’ which is a monoclonal antibody that is used to remove amyloid plaque from the brain of an Alzheimer’s patient. It is investigational compound having mechanism of action targeted at the early stages of Alzheimer's disease. Founded in 1896, Roche is headquartered in Switzerland’s Basel town. The company has a strong R&D infrastructure, having 22 established centers around the world.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET -SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. KEY FINDINGS

2.8. INDUSTRY STRUCTURE

2.8.1. RESEARCH AND DEVELOPMENT

2.8.2. MANUFACTURING

2.8.3. RAW MATERIALS

2.8.4. END USER

2.8.5. WHOLESALERS

2.9. REGULATORY FRAMEWORK

2.10. THE UNITED STATES AND EUROPE REGULATORY AGENCY

2.11. ALZHEIMER'S DISEASE ETIOLOGY

2.12. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.13. MARKET DRIVERS

2.13.1. GROWTH OF THE ALZHEIMER’S DISEASE

2.13.2. GROWING GERIATRIC POPULATION

2.13.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.14. MARKET RESTRAINTS

2.14.1. STRINGENT GOVERNMENT REGULATIONS

2.14.2. THE TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH

2.15. MARKET OPPORTUNITIES

2.15.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.15.2. R&D INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING

2.16. MARKET CHALLENGES

2.16.1. AWARENESS IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE

2.16.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE

3.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.3. PRODROMAL STAGE

3.1.4. THERAPEUTICS BY GENERIC AND BRANDED

3.1.4.1. BRANDED

3.1.4.2. GENERIC

3.2. DIAGNOSTIC TYPE

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – EUROPE

4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2. COUNTRY ANALYSIS

4.2.1. THE UNITED KINGDOM

4.2.2. FRANCE

4.2.3. GERMANY

4.2.4. SPAIN

4.2.5. ITALY

4.2.6. RUSSIA

4.2.7. REST OF EUROPE

5.    COMPANY PROFILES

5.1. ABBVIE

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER

5.5. BIOGEN

5.6. COGNOPTIX

5.7. DIAGENIC ASA

5.8. ROCHE

5.9. GE HEALTHCARE

5.10. MERCK

5.11. JOHNSON & JOHNSON

5.12. PIRAMAL ENTERPRISES LTD.

5.13. SIEMENS HEALTHINEERS AG

5.14. SUN PHARMACEUTICAL INDUSTRIES LTD.

6.    RESEARCH METHODOLOGY & SCOPE

6.1. RESEARCH SCOPE & DELIVERABLES

6.1.1. OBJECTIVES OF STUDY

6.1.2. SCOPE OF STUDY

6.2. SOURCES OF DATA

6.2.1. PRIMARY DATA SOURCES

6.2.2. SECONDARY DATA SOURCES

6.3. RESEARCH METHODOLOGY

6.3.1. EVALUATION OF PROPOSED MARKET

6.3.2. IDENTIFICATION OF DATA SOURCES

6.3.3. ASSESSMENT OF MARKET DETERMINANTS

6.3.4. DATA COLLECTION

6.3.5. DATA VALIDATION & ANALYSIS

           

      

List of table

TABLE 1        EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 2        EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS2019-2027 ($ MILLION)

TABLE 3        EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS2019-2027 ($ MILLION)

TABLE 4        EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED2019-2027 ($ MILLION)

TABLE 5        EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

TABLE 6        EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 7        EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)

List of Figures

FIGURE 1      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 2      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)

FIGURE 3      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS2019-2027 ($ MILLION)

FIGURE 4      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)

FIGURE 5      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD2019-2027 ($ MILLION)

FIGURE 6      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD2019-2027 ($ MILLION)

FIGURE 7      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)

FIGURE 8      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED2019-2027 ($ MILLION)

FIGURE 9      EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC2019-2027 ($ MILLION)

FIGURE 10   EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

FIGURE 11   EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST2019-2027 ($ MILLION)

FIGURE 12   EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY2019-2027 ($ MILLION)

FIGURE 13   EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY2019-2027 ($ MILLION)

FIGURE 14   EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING2019-2027 ($ MILLION)

FIGURE 15   EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY2019-2027 ($ MILLION)

FIGURE 16   EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS2019-2027 ($ MILLION)

FIGURE 17   THE UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 18   FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 19   GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 20   SPAIN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 21   ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 22   RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 23   REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

 

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;